Nanobiotix SA
PAR:NANO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nanobiotix SA
PAR:NANO
|
FR |
|
Bark Inc
NYSE:BARK
|
US |
|
Marimekko Oyj
OTC:MKKOF
|
FI |
|
Bizim Toptan Satis Magazalari AS
IST:BIZIM.E
|
TR |
|
Impinj Inc
NASDAQ:PI
|
US |
|
Cambridge Cognition Holdings PLC
LSE:COG
|
UK |
|
Southern Missouri Bancorp Inc
NASDAQ:SMBC
|
US |
|
Calin Technology Co Ltd
TWSE:4976
|
TW |
|
P
|
Parque Arauco SA
SGO:PARAUCO
|
CL |
|
T
|
Tabula Rasa HealthCare Inc
F:43T
|
US |
|
A O Smith Corp
NYSE:AOS
|
US |
|
Y
|
Young Poong Precision Corp
KOSDAQ:036560
|
KR |
Nanobiotix SA
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
J&J partnership: Nanobiotix said the Johnson & Johnson collaboration kept advancing in 2025, with Phase III head and neck work continuing and a new Phase Ib head and neck study and lung cancer study broadening the opportunity set.
Lung data: Early CONVERGE data from the first 7 patients showed 5 of 7 responses, 100% disease control, no serious adverse events tied to treatment, and feasibility of injection in every patient, but management stressed it is still only a small safety lead-in.
Cash runway: The company said cash and cash equivalents were EUR 52.8 million at year-end 2025 and now expect funding into early 2028, assuming receipt of the remaining $21 million from Healthcare Royalty Partners in Q4 2026.
Financial profile: Full-year revenue was EUR 32.6 million, R&D expense fell to EUR 23.1 million, SG&A was EUR 20.4 million, and net loss improved to EUR 24 million, or EUR 0.50 per share.
Curadigm push: Nanobiotix continues to build its new Curadigm platform, filing 4 new patent applications, starting GMP manufacturing and pre-IND work, and signing more than 20 MTAs with pharma and biotech partners.
2026-27 catalysts: Management highlighted multiple upcoming clinical readouts, including the Phase III head and neck readout in the first half of 2027, the Phase II lung readout in early 2027, and additional trial data later this year and into 2026.
